New shot for eczema shows promise in large trial
NCT ID NCT06468956
First seen Oct 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This study tests an experimental drug called SHR-1819 for people with moderate to severe atopic dermatitis (eczema). About 652 adults will receive either the drug or a placebo to see if it improves skin symptoms and reduces itching. The main goal is to measure skin clearing and itch relief after 16 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Fudan University HuaShan Hospital
Shanghai, Shanghai Municipality, 200040, China
Conditions
Explore the condition pages connected to this study.